AT-Patch Medical Device United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

at-patch medical device

al inmaa drug store & medical equipments llc korea (south) - 1 device unit (atp-c130) accessory kit (atacc-c130e) - device - medical device - medical devices-medical devices

AL-Cefuroxime cefuroxime 250mg film coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

al-cefuroxime cefuroxime 250mg film coated tablet blister pack

pharmacor pty ltd - cefuroxime axetil, quantity: 300.715 mg - tablet, film coated - excipient ingredients: crospovidone; croscarmellose sodium; calcium carbonate; calcium stearate; purified water; colloidal anhydrous silica; microcrystalline cellulose; sodium lauryl sulfate; titanium dioxide; hypromellose; propylene glycol; brilliant blue fcf aluminium lake - cefuroxime is indicated for the treatment of the following mild to moderately severe infections in adults caused by sensitive bacteria: acute upper respiratory infections: otitis media, sinusitis, tonsillitis and pharyngitis. acute exacerbations of chronic bronchitis, or acute bronchitis. skin and skin structure infections for example, furunculosis, pyoderma and impetigo. acute uncomplicated gonococcal urethritis, and cervicitis due to non-penicillinase producing gonococci.

AL-Cefuroxime cefuroxime 500mg film coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

al-cefuroxime cefuroxime 500mg film coated tablet blister pack

pharmacor pty ltd - cefuroxime axetil, quantity: 601.43 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; crospovidone; calcium stearate; microcrystalline cellulose; sodium lauryl sulfate; purified water; calcium carbonate; croscarmellose sodium; titanium dioxide; hypromellose; propylene glycol; brilliant blue fcf aluminium lake - cefuroxime is indicated for the treatment of the following mild to moderately severe infections in adults caused by sensitive bacteria: acute upper respiratory infections: otitis media, sinusitis, tonsillitis and pharyngitis. acute exacerbations of chronic bronchitis, or acute bronchitis. skin and skin structure infections for example, furunculosis, pyoderma and impetigo. acute uncomplicated gonococcal urethritis, and cervicitis due to non-penicillinase producing gonococci.

ZISHEL ROSE FORTE 20mg / ml Injection United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

zishel rose forte 20mg / ml injection

wahat al salam pharmaceutical & medical equipment korea (south) - 1x1ml pre-filled syringe - injection - 20mg / ml - skin-n/a

PLIDOGREL clopidogrel (as besilate) 75 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

plidogrel clopidogrel (as besilate) 75 mg tablet blister pack

arrotex pharmaceuticals pty ltd - clopidogrel besilate, quantity: 112.1 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: mannitol; polyethylene glycol monomethyl ether; iron oxide red; stearic acid; hyprolose; purified talc; citric acid monohydrate; hypromellose; lactose monohydrate; microcrystalline cellulose; triacetin; crospovidone; titanium dioxide - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. acute coronary syndrome: plidogrel is indicated in combination with aspirin for patients with: unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). plidogrel is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent); st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, plidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.